Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
The goal of therapeutic drug monitoring (TDM) is to optimize anti-TNF (tumor necrosis factor) biologic treatment in patients with inflammatory bowel disease (IBD). Although commercial assays are readily available for both ustekinumab and vedolizumab, the use of TDM with these newer biologic medicati...
Main Authors: | Sophie Restellini, Waqqas Afif |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/6/1242 |
Similar Items
-
Second Mexican consensus on biologic therapy and small-molecule inhibitors in inflammatory bowel disease
by: J.K. Yamamoto-Furusho, et al.
Published: (2021-01-01) -
Emerging Therapies: What Are Promising in the Near Future?
by: Geom Seog Seo, et al.
Published: (2018-02-01) -
Segundo Consenso Mexicano de terapia biológica y moléculas pequeñas en enfermedad inflamatoria intestinal
by: J.K. Yamamoto-Furusho, et al.
Published: (2021-01-01) -
Cost-effectiveness of ustekinumab in moderate to severe Crohn’s disease in Sweden
by: Amanda Hansson-Hedblom, et al.
Published: (2018-08-01) -
Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
by: Benjamin Crooks, et al.
Published: (2020-03-01)